The widening loss and cash burn are expected for a pre-commercial biotech, but the stock will trade on the PDUFA date (July 7, 2026) and PIONEER Phase 2 data (expected Q2 2026). Monitor for any FDA advisory committee meeting announcement or label expansion data.
VERA drugs
VERA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $35.88entry
- T+1 · 6mo ago +0.86%α +0.03% · $36.19
- T+5 · 6mo ago +9.11%α +7.61% · $39.15
- T+20 · 6mo ago −12.85%α −15.98% · $31.27
- T+60 · 4mo ago −10.17%α −14.01% · $32.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vera Therapeutics reported Q1 2026 results with a net loss of $1.69 per share, wider than the $0.81 loss in Q1 2025, driven by increased R&D and G&A spending ahead of a potential atacicept launch. The company maintains a strong cash position of $596.8M and is on track for a mid-2026 U.S. commercial launch pending FDA approval by July 7, 2026.
Key Financial Metrics
Key Facts
- Net loss per diluted share of $1.69 for Q1 2026 vs $0.81 in Q1 2025
- Cash, cash equivalents, and marketable securities of $596.8M as of March 31, 2026
- FDA PDUFA target action date for atacicept BLA is July 7, 2026
- Company expects U.S. commercial launch of atacicept in mid-2026, pending approval
- Net cash used in operating activities was $106.5M in Q1 2026 vs $54.4M in Q1 2025
Financial Impact
Net loss widened to $121.0M from $51.7M YoY; cash burn increased to $106.5M from $54.4M
Risk Factors
- FDA non-approval or delay of atacicept BLA
- Higher-than-expected cash burn rate could require additional financing
- Competitive landscape in IgA nephropathy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210351 |
| Document: vera-20260507.htm | 0001193125-26-210351 |
| Document: 0001193125-26-210351-index-headers.html | 0001193125-26-210351 |
| Document: 0001193125-26-210351-index.html | 0001193125-26-210351 |
| Document: 0001193125-26-210351.txt | 0001193125-26-210351 |
| 8-K Data (Synthetic) | 0001193125-26-210351 |
Track record
25 reports on VERA
13 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 14 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers